Lenalidomide in low and int-1 risk MDS with del5q: efficacy and quality of life

被引：0
|
作者：
Oliva, E. [1 ]
Latagliata, R. [2 ]
Breccia, M. [2 ]
Morabito, F. [3 ]
Ghio, R. [4 ]
Poloni, A. [5 ]
Barate, C. [6 ]
Cortelezzi, A. [7 ]
Ricco, A. [8 ]
Alati, C. [1 ]
Spiriti, M. Aloe [9 ]
Nobile, F. [1 ]
机构：
[1] Azienda Osped BMM, Hematol Unit, Reggio Di Calabria, Italy
[2] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy
[3] Azienda Osped Cosenza, Hematol Unit, Cosenza, Italy
[4] Osped San Martino Genova, Genoa, Italy
[5] Osped Torrette Ancona, Ancona, Italy
[6] Univ Pisa, Dept Oncol Transplant & New Technol Med, I-56100 Pisa, Italy
[7] Osped Maggiore, Milan, Italy
[8] Univ Bari, I-70121 Bari, Italy
[9] Azienda Osped St Andrea, Rome, Italy
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70191-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S123 / S123
页数：1
相关论文
共 50 条
  • [1] Azacitidine (AZA) After Failure of Lenalidomide (LEN) in Low/Int-1 Risk MDS with Del 5q
    Bally, Cecile
    Itzykson, Raphael
    Gruson, Berangere
    Francois, Dreyfus
    Siguret, Virginie
    Taksin, Anne-Laure
    de Renzis, Benoit
    Legros, Laurence
    Thomas, Xavier
    Bouabdallah, Krimo
    Chaibi, Pascal
    Kelaidi, Charikleia
    Fenaux, Pierre
    Ades, Lionel
    BLOOD, 2011, 118 (21) : 1200 - 1201
  • [2] Lenalidomide for the Treatment of Low- and Int-1-Risk MDS with Del(5q): Efficacy and Quality of Life Study.
    Oliva, Esther Natalie
    Latagliata, Roberto
    Morabito, Fortunato
    Poloni, Antonella
    Ghio, Riccardo
    Cortelezzi, Agostino
    Finelli, Carlo
    Barate, Claudia
    Ronco, Francesca
    Spiriti, Maria Antonietta Aloe
    Ricco, Alessandra
    Breccia, Massimo
    Alati, Caterina
    Pratico, Giulia
    Nobile, Francesco
    BLOOD, 2009, 114 (22) : 1080 - 1080
  • [3] ECONOMIC EVALUATION OF LENALIDOMIDE IN THE TREATMENT OF LOWER RISK MYELODYSPLASTIC SYNDROMES WITH DEL5Q (MDS DEL5Q) IN MEXICO
    Ramos, C.
    Montano, E.
    Reyes Lopez, A.
    Pacheco-Alvarez, I
    Hernandez-Rivera, G.
    Lemus-Carmona, E. A.
    VALUE IN HEALTH, 2016, 19 (03) : A248 - A248
  • [4] A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q)
    V Sardnal
    A Rouquette
    S Kaltenbach
    C Bally
    V Chesnais
    C Leschi
    L Ades
    V Santini
    S Park
    A Toma
    P Fenaux
    F Dreyfus
    M Fontenay
    O Kosmider
    Leukemia, 2013, 27 : 1610 - 1613
  • [5] A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q)
    Sardnal, V.
    Rouquette, A.
    Kaltenbach, S.
    Bally, C.
    Chesnais, V.
    Leschi, C.
    Ades, L.
    Santini, V.
    Park, S.
    Toma, A.
    Fenaux, P.
    Dreyfus, F.
    Fontenay, M.
    Kosmider, O.
    LEUKEMIA, 2013, 27 (07) : 1610 - 1613
  • [6] Gene expression patterns in MDS with del5q before and during lenalidomide treatment
    Oliva, E.
    Cuzzola, M.
    Iacopino, G.
    Alimena, G.
    Latagliata, R.
    Morabito, F.
    Galimberti, S.
    Ghio, R.
    Poloni, A.
    Specchia, G.
    Lagana, C.
    DErrigo, M.
    Modafferi, B.
    Cortelezzi, A.
    Nobile, F.
    LEUKEMIA RESEARCH, 2009, 33 : S124 - S124
  • [7] IMPACT OF LENALIDOMIDE ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RBC TRANSFUSION-DEPENDENT LOW-OR INT-1-RISK MYELODYSPLASTIC SYNDROMES WITH DEL5Q: A RANDOMIZED PHASE 3 STUDY (MDS-004)
    Brandenburg, N.
    Fu, T.
    Revicki, D.
    Knight, R.
    Muus, P.
    Fenaux, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 127 - 127
  • [8] RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004)
    Fenaux, Pierre
    Giagounidis, Aristotle
    Selleslag, Dominik
    Beyne-Rauzy, Odile
    Mufti, Ghulam J.
    Mittelman, Moshe
    Muus, Petra
    te Boekhorst, Peter
    Sanz, Guillermo
    del Canizo, Consuelo
    Guerci-Bresler, Agnes
    Schlegelberger, Brigitte
    Aul, Carlo
    Kreipe, Hans
    Goehring, Gudrun
    Knight, Robert
    Francis, John
    Fu, Tommy
    Hellstrom-Lindberg, Eva
    BLOOD, 2009, 114 (22) : 390 - 390
  • [9] Prognostic Factors of Long-Term Outcomes In Low- or Int-1-Risk MDS with del5q Treated with Lenalidomide (LEN): Results From a Randomized Phase 3 Trial (MDS-004)
    Fenaux, Pierre
    Giagounidis, Aristotles
    Beyne-Rauzy, Odile
    Mufti, Ghulam
    Mittelman, Moshe
    Muus, Petra
    Boekhorst, Peter Te
    Sanz, Guillermo
    Cazzola, Mario
    Backstrom, Jay
    Fu, Tommy
    Hellstrom-Lindberg, Eva
    BLOOD, 2010, 116 (21) : 1641 - 1641
  • [10] MDS/AML with del5q: An acquired "laminopathy"?
    Papapetrou, Eirini P.
    CELL STEM CELL, 2022, 29 (04) : 498 - 499
12345